Leerink Partnrs Estimates Merus’ Q1 Earnings (NASDAQ:MRUS)

Merus (NASDAQ:MRUS) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for Merus in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the biotechnology company will post earnings of ($1.18) per share for the quarter. The consensus estimate for Merus’ current full-year earnings is ($3.89) per share. Leerink Partnrs also issued estimates for Merus’ Q2 2025 earnings at ($1.26) EPS and Q3 2025 earnings at ($1.30) EPS.

MRUS has been the subject of several other research reports. Needham & Company LLC restated a “buy” rating and set a $85.00 price target on shares of Merus in a research note on Monday, December 9th. The Goldman Sachs Group assumed coverage on shares of Merus in a research note on Thursday, November 21st. They issued a “buy” rating and a $73.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $85.00 target price on shares of Merus in a report on Monday, December 2nd. UBS Group started coverage on shares of Merus in a report on Thursday, October 24th. They set a “buy” rating and a $72.00 price target for the company. Finally, Guggenheim reaffirmed a “buy” rating and issued a $109.00 price objective (down previously from $111.00) on shares of Merus in a report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, twelve have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $85.64.

Merus Price Performance

Shares of Merus stock opened at $41.54 on Friday. The company’s fifty day moving average is $42.24 and its two-hundred day moving average is $47.86. Merus has a 1 year low of $35.67 and a 1 year high of $61.61.

Institutional Investors Weigh In On Merus

Several large investors have recently added to or reduced their stakes in MRUS. nVerses Capital LLC boosted its stake in Merus by 750.0% during the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 1,500 shares during the period. Avior Wealth Management LLC acquired a new position in shares of Merus during the fourth quarter worth approximately $76,000. US Bancorp DE bought a new position in Merus in the 3rd quarter worth approximately $103,000. Mirae Asset Global Investments Co. Ltd. increased its position in Merus by 24.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company’s stock valued at $118,000 after acquiring an additional 489 shares during the period. Finally, MML Investors Services LLC bought a new stake in Merus during the 3rd quarter valued at $206,000. 96.14% of the stock is owned by institutional investors and hedge funds.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.